2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). (September 2015) - Shore, N.; Bailen, J.; Pieczonka, C.; MacLean, D.; Shi, H.; Faessel, H.; Saad, F.